Roche Pharmaceutical Development and Sales Overview
gRED oncology development programs -1
Roche
Molecule
Indication
Phase
# of patients
Status
CT Identifier
Oncology
KRAS G12C (RG6330)
Metastatic solid tumors with KRAS
G12C mutation
FPI Q3 2020
270
NCT04449874
Data presented at WCLC 2022, ESMO 2022
FPI Q3 2017
cevostamab
(anti-FcRH5 x CD3; RG6160)
R/R multiple myeloma
300
NCT03275103
Data presented at ASH 2020, ASH 2021
R/R multiple myeloma
120
FPI Q2 2021
NCT04910568
runimotamab
Metastatic HER2-expressing cancers
440
FPI Q2 2018
NCT03448042
(HER2 x CD3, RG6194)
NME (RG6286)
Locally advanced or metastatic
colorectal cancer
Solid tumors
IL15/IL15Ra-Fc (RG6323)¹
R/R multiple myeloma
autogene cevumeran
(Individualized Neoantigen-Specific
Therapy (iNeST); RG6180)²
Solid tumors
67
FPI Q3 2020
1/11
250
FPI Q1 2020
|
60
FPI Q2 2022
FPI Q4 2017
la/llb
271
Data presented at AACR 2020
NCT04468607
NCT04250155
NCT05243342
Recruitment completed Q1 2022
NCT03289962
SHP2i (RG6344)3³
Partner: 1Xencor, 2BioNTech, ³Relay, "Hanmi
132
FPI Q1 2019
la
~50
FPI Q1 2020
lb
~125
FPI Q3 2022
1L advanced melanoma
||
=
Solid tumors
Solid tumors
NCT03815058
(IMcode001)
NCT04252339
NCT05487235
137View entire presentation